Action mechanism of Ginkgo biloba leaf extract intervened by exercise therapy in treatment of benign prostate hyperplasia

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Peng, Chiung Chi ^a   Liu, Jia Hong ^b,c   Chang, Chi Huang ^b   Chung, Jin Yuan ^a,d   Chen, Kuan Chou ^d   Chou, Kuang Yu ^e   Peng, Robert Y ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; AROMATASE; CERENIN; CYCLINE; ESTRADIOL; ESTROGEN RECEPTOR; GINKGO BILOBA EXTRACT; MINERAL OIL; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GINKGO BILOBA; KINESIOTHERAPY; MALE; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 84877249110     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/408734     Document Type: Article

References (36)

1. McVary K. T., BPH: epidemiology and comorbidities. American Journal of Managed Care 2006 12 5, supplement S122 S128 2-s2.0-33645956542
2. Nicholson T. M., Ricke W. A., Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011 82 4-5 184 199
3. McNeal J., Pathology of benign prostatic hyperplasia. Insight into etiology. Urologic Clinics of North America 1990 17 3 477 486 2-s2.0-0025296064 (Pubitemid 20220191)
4. Untergasser G., Madersbacher S., Berger P., Benign prostatic hyperplasia: age-related tissue-remodeling. Experimental Gerontology 2005 40 3 121 128 2-s2.0-14844301664 10.1016/j.exger.2004.12.008 (Pubitemid 40343002)
5. Lucia M. S., Lambert J. R., Growth factors in benign prostatic hyperplasia: basic science implications. Current Urology Reports 2008 9 4 272 278 2-s2.0-48749119744 10.1007/s11934-008-0048-6
6. Sciarra A., Mariotti G., Salciccia S., Gomez A. A., Monti S., Toscano V., Di Silverio F., Prostate growth and inflammation. Journal of Steroid Biochemistry and Molecular Biology 2008 108 3-5 254 260 2-s2.0-38749135796 10.1016/j.jsbmb.2007.09.013 (Pubitemid 351179630)
7. Ho C. K. M., Habib F. K., Estrogen and androgen signaling in the pathogenesis of BPH. Nature Reviews Urology 2011 8 1 29 41 2-s2.0-78651357284 10.1038/nrurol.2010.207
8. Tsurusaki T., Aoki D., Kanetake H., Inoue S., Muramatsu M., Hishikawa Y., Koji T., Zone-dependent expression of estrogen receptors α and β in human benign prostatic hyperplasia. The Journal of Clinical Endocrinology and Metabolism 2003 88 3 1333 1340 2-s2.0-0037340497 10.1210/jc.2002-021015 (Pubitemid 36337798)
9. Alonso-Magdalena P., Brössner C., Reiner A., Cheng G., Sugiyama N., Warner M., Gustafsson J. Å., A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proceedings of the National Academy of Sciences of the United States of America 2009 106 8 2859 2863 2-s2.0-62449153891 10.1073/pnas.0812666106
10. Lin S. Y., Chang H. P., Induction of superoxide dismutase and catalase activity in different rat tissues and protection from UVB irradiation after topical application of Ginkgo biloba extracts. Methods and Findings in Experimental and Clinical Pharmacology 1997 19 6 367 371 2-s2.0-0030830797
11. Berger A. P., Kofler K., Bektic J., Rogatsch H., Steiner H., Bartsch G., Klocker H., Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003 57 1 57 65 2-s2.0-0042830775 10.1002/pros.10279 (Pubitemid 37070150)
12. Kramer G., Mitteregger D., Marberger M., Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology 2007 51 5 1202 1216 2-s2.0-33947247395 10.1016/j.eururo.2006.12.011 (Pubitemid 46436310)
13. Novara G., Galfano A., Ficarra V., Artibani W., Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. European Urology 2006 50 4 675 683 2-s2.0-33748335370 10.1016/j.eururo.2006.07.017 (Pubitemid 44332687)
14. Delongchamps N. B., de la Roza G., Chandan V., Jones R., Sunheimer R., Threatte G., Jumbelic M., Haas G. P., Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? Journal of Urology 2008 179 5 1736 1740 2-s2.0-41749117503 10.1016/j.juro.2008.01.034
15. Nickel J. C., Roehrborn C. G., O'Leary M. P., Bostwick D. G., Somerville M. C., Rittmaster R. S., Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. Journal of Urology 2007 178 3 896 901 2-s2.0-34547677616 10.1016/j.juro.2007.05.041 (Pubitemid 47211075)
16. Alcaraz A., Hammerer P., Tubaro A., Schröder F. H., Castro R., Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. European Urology 2009 55 4 864 873 2-s2.0-60249084251 10.1016/j.eururo.2008.11.011
17. Roehrborn C. G., Barkin J., Siami P., Tubaro A., Wilson T. H., Morrill B. B., Gagnier R. P., Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-Year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. Journal of the British Association of Urological Surgeons 2011 107 6 946 954 2-s2.0-79952584014 10.1111/j.1464-410X.2011.10124.x
18. Gerber G. S., Phytotherapy for benign prostatic hyperplasia. Current Urology Reports 2002 3 4 285 291 2-s2.0-0036673059
19. Thomas J. A., Diet, micronutrients, and the prostate gland. Nutrition Reviews 1999 57 4 95 103 2-s2.0-0032966546 (Pubitemid 29206384)
20. Singh B., Kaur P., Gopichand, Singh R. D., Ahuja P. S., Biology and chemistry of Ginkgo biloba. Fitoterapia 2008 79 6 401 418 2-s2.0-49849102480 10.1016/j.fitote.2008.05.007
21. Gohil K., Moy R. K., Farzin S., Maguire J. J., Packer L., MRNA expression profile of a human cancer cell line in response to Ginkgo biloba extract: induction of antioxidant response and the golgi system. Free Radical Research 2000 33 6 831 849 2-s2.0-0034466454 (Pubitemid 32208491)
22. Bridi R., Crossetti F. P., Steffen V. M., Henriques A. T., The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytotherapy Research 2001 15 5 449 451 2-s2.0-0034883315 10.1002/ptr.814 (Pubitemid 32762399)
23. Chen J. X., Zeng H., Chen X., Su C. Y., Lai C. C., Induction of oxygenase-1 by Ginkgo biloba extract but not its terpenoids partially mediated its protective effect against lysophosphatidylcholine-induced damage. Pharmacological Research 2001 43 1 63 69 2-s2.0-0034743633 10.1006/phrs.2000. 0753 (Pubitemid 32577756)
24. Ahmad M., Saleem S., Ahmad A. S., Yousuf S., Ansari M. A., Khan M. B., Ishrat T., Chaturvedi R. K., Agrawal A. K., Islam F., Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. Journal of Neurochemistry 2005 93 1 94 104 2-s2.0-20144386944 10.1111/j.1471-4159.2005. 03000.x (Pubitemid 40463519)
25. DeFeudis F. V., A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry 2003 36 supplement 1 S2 S7 2-s2.0-0042827395
26. Shah G. R., Chaudhari M. V., Patankar S. B., Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study. BMC Complementary and Alternative Medicine 2012 12 155 163
27. Sea J., Poon K. S., McVary K. T., Review of exercise and the risk of benign prostatic hyperplasia. The Physician and Sportsmedicine 2009 37 4 75 83 2-s2.0-76149122140
28. Williams P. T., Effects of running distance and performance on incident benign prostatic hyperplasia. Medicine and Science in Sports and Exercise 2008 40 10 1733 1739 2-s2.0-58149296066 10.1249/MSS.0b013e31817b8eba
29. Suzuki K., Takezawa Y., Suzuki T., Honma S., Yamanaka H., Synergistic effects of estrogen with androgen on the prostate-effects of estrogen on the prostate of androgen-administered rats and 5-alpha-reductase activity. Prostate 1994 25 4 169 176 2-s2.0-0028064511 10.1002/pros.2990250402 (Pubitemid 24302132)
30. Chen K. C., Hsieh C. L., Peng C. C., Peng R. Y., Exercise rescued chronic kidney disease by attenuating cardiac hypertrophy through the cardiotrophin-1 → LIFR/gp 130 →JAK/STAT3 pathway. European Journal of Preventive Cardiology 2012 10.1177/2047487312462827
31. Chen J. S., Chen Y. H., Huang P. H., Ginkgo biloba extract reduces high-glucose-induced endothelial adhesion by inhibiting the redox-dependent interleukin-6 pathways. Cardiovascular Diabetology 2012 11 49
32. Ma J., Gharaee-Kermani M., Kunju L., Prostatic fibrosis is associated with lower urinary tract symptoms. Journal of Urology 2012 188 4 1375 1381
33. Ulman C., Buyukyazi G., Taneli F., Uyanik B. S., Recreational and master athletic activity does not affect free and total prostate-specific antigen levels but lowers the free-to-total prostate-specific antigen ratio. Journal of International Medical Research 2004 32 6 583 589 2-s2.0-9444263054 (Pubitemid 39561762)
34. Oh S. M., Chung K. H., Antiestrogenic activities of Ginkgo biloba extracts. Journal of Steroid Biochemistry and Molecular Biology 2006 100 4-5 167 176 2-s2.0-33746820211 10.1016/j.jsbmb.2006.04.007 (Pubitemid 44175838)
35. Giri D., Ittmann M., Interleukin-1 α is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. American Journal of Pathology 2000 157 1 249 255 2-s2.0-0033624034 (Pubitemid 30641741)
36. Deng F., Gu F., Xia T., Proliferation and apoptosis status in benign prostatic hyperplasia. Zhonghua Wai Ke Za Zhi 1996 34 10 620 622 2-s2.0-0030251938